A novel platform to hurry up antimicrobial susceptibility testing in Neisseria gonorrhoeae using RNA
October 5, 2020
A novel platform to hurry up antimicrobial susceptibility testing in Neisseria gonorrhoeae using RNA signatures
The rise of antimicrobial-resistant pathogens could possibly be attributed to the scarcity of a speedy pathogen identification (ID) or antimicrobial susceptibility testing (AST), resulting in delayed therapeutic decisions on the point-of-care. Gonorrhea is usually empirically dealt with with no AST outcomes obtainable sooner than remedy, thus contributing to the speedy rise in drug resistance.
Herein we present a speedy AST platform using RNA signatures for Neisseria gonorrhoeae (NG). RNA-seq adopted by bioinformatic devices had been utilized to find potential markers throughout the transcriptome profile of NG upon minutes of azithromycin publicity. Validation of candidate markers using qRT-PCR confirmed that two markers (arsR (NGO1562) and rpsO) can ship appropriate AST outcomes all through 14 examined isolates.
Extra validation of our susceptibility threshold in comparison with MIC all through 64 additional isolates confirmed the reliability of our platform. Our RNA markers combined with rising molecular point-of-care applications has the potential to considerably pace up every ID and AST to inform remedy.
Description: BDNF is a member of the NGF family of neurotrophic growth factors. Like other members of this family, BDNF supports neuron proliferation and survival. BDNF can bind to a low affinity cell surface receptor called LNGFR, which also binds other neurotrophins such as NGF, NT-3 and NT-4. However, BDNF mediates its neurotrophic properties by signaling through a high affinity cell surface receptor called gp145/trkB. BDNF is expressed as the C-terminal portion of a 247 amino acid polypeptide precursor, which also contains a signal sequence of 18 amino acid residue and a propeptide of 110 amino acid residues. Recombinant human BDNF is a 27.0 kDa homodimer of two 119 amino acid subunits linked by strong non-covalent interactions. Human and Mouse BDNF sequences are identical.
Description: BDNF is a member of the NGF family of neurotrophic growth factors. Like other members of this family, BDNF supports neuron proliferation and survival. BDNF can bind to a low affinity cell surface receptor called LNGFR, which also binds other neurotrophins such as NGF, NT-3 and NT-4. However, BDNF mediates its neurotrophic properties by signaling through a high affinity cell surface receptor called gp145/trkB. BDNF is expressed as the C-terminal portion of a 247 amino acid polypeptide precursor, which also contains a signal sequence of 18 amino acid residue and a propeptide of 110 amino acid residues. Recombinant human BDNF is a 27.0 kDa homodimer of two 119 amino acid subunits linked by strong non-covalent interactions. Human and Mouse BDNF sequences are identical.
Description: Brain-derived neurotrophic factor (BDNF) is a member of the NGF family of neurotrophic factors (also named neurotrophins) that are required for the differentiation and survival of specific neuronal subpopulations in both the central as well as the peripheral nervous system. The neurotrophin family comprises at least four proteins including NGF, BDNF, NT3, and NT4/ 5. These secreted cytokines are synthesized as prepropeptides that are proteolytically processed to generate the mature proteins. All neurotrophins have six conserved cysteine residues that are involved in the formation of three disulfide bonds and all share approximately 55% sequence identity at the amino acid level. Similarly to NGF, bioactive BDNF is predicted to be a noncovalently linked homodimer. BDNF cDNA encodes a 247 amino acid residue precursor protein with a signal peptide and a proprotein that are cleaved to yield the 119 amino acid residue mature BDNF. The amino acid sequence of mature BDNF is identical in all mammals examined. High levels of expression of BDNF have been detected in the hippocampus, cerebellum, fetal eye, and placenta. In addition, low levels of BDNF expression are also found in the pituitary gland, spinal cord, heart, lung, and skeletal muscle. BDNF binds with high affinity and specifically activates the TrkB tyrosine kinase receptor.
Description: BDNF is a member of the NGF family of neurotrophic growth factors. Like other members of this family, BDNF supports neuron proliferation and survival. BDNF can bind to a low affinity cell surface receptor called LNGFR, which also binds other neurotrophins such as NGF, NT-3 and NT-4. However, BDNF mediates its neurotrophic properties by signaling through a high affinity cell surface receptor called gp145/trkB. BDNF is expressed as the C-terminal portion of a 247 amino acid polypeptide precursor, which also contains a signal sequence of 18 amino acid residue and a propeptide of 110 amino acid residues. Recombinant human BDNF is a 27.0 kDa homodimer of two 119 amino acid subunits linked by strong non-covalent interactions. Human and Mouse BDNF sequences are identical.
Description: A polyclonal antibody for BDNF from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the N-terminal of human BDNF. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BDNF antibody is conjugated to ATTO 565.
Description: A polyclonal antibody for BDNF from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the N-terminal of human BDNF. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BDNF antibody is conjugated to ATTO 633.
Description: A polyclonal antibody for BDNF from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the N-terminal of human BDNF. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BDNF antibody is conjugated to ATTO 655.
Description: A polyclonal antibody for BDNF from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the N-terminal of human BDNF. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BDNF antibody is conjugated to ATTO 680.
Description: A polyclonal antibody for BDNF from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the N-terminal of human BDNF. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BDNF antibody is conjugated to ATTO 700.
Description: A polyclonal antibody for BDNF from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the N-terminal of human BDNF. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BDNF antibody is conjugated to APC/Cy7.
Description: A polyclonal antibody for BDNF from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the N-terminal of human BDNF. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BDNF antibody is conjugated to Dylight 350.
Description: A polyclonal antibody for BDNF from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the N-terminal of human BDNF. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BDNF antibody is conjugated to Dylight 405.
Description: A polyclonal antibody for BDNF from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the N-terminal of human BDNF. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BDNF antibody is conjugated to Dylight 488.
Description: A polyclonal antibody for BDNF from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the N-terminal of human BDNF. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BDNF antibody is conjugated to Dylight 594.
Description: A polyclonal antibody for BDNF from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the N-terminal of human BDNF. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BDNF antibody is conjugated to Dylight 633.
Description: A polyclonal antibody for BDNF from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the N-terminal of human BDNF. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BDNF antibody is conjugated to PE/ATTO 594.
Description: A polyclonal antibody for BDNF from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the N-terminal of human BDNF. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BDNF antibody is conjugated to Streptavidin.
Description: BDNF is found in neurons of the central nervous system. It is expressed predominantly in hippocampus, cortex, and synapses of the basal forebrain. The biological activity of BDNF is mediated by a receptor that belongs to the trk family of receptors encoding a tyrosine-specific protein kinase. BDNF only binds weakly to the gp140trk receptor (to which NGF binds with high affinity), and it binds to the NGF receptor known as LNGFR. BDNF selectively supports the survival of primary sensory neurons and retinal ganglia. The factor supports survival and differentiation of certain cholinergic neurons and also some dopaminergic neurons in vitro. BDNF does not appear to act on sympathetic ganglia. In specific neurons of the central nervous system located in the hippocampus and the cortex the synthesis of BDNF is influenced by neuronal activity either positively (glutamate transmitter system) or negatively (GABA transmitter system).
Description: BDNF is found in neurons of the central nervous system. It is expressed predominantly in hippocampus, cortex, and synapses of the basal forebrain. The biological activity of BDNF is mediated by a receptor that belongs to the trk family of receptors encoding a tyrosine-specific protein kinase. BDNF only binds weakly to the gp140trk receptor (to which NGF binds with high affinity), and it binds to the NGF receptor known as LNGFR. BDNF selectively supports the survival of primary sensory neurons and retinal ganglia. The factor supports survival and differentiation of certain cholinergic neurons and also some dopaminergic neurons in vitro. BDNF does not appear to act on sympathetic ganglia. In specific neurons of the central nervous system located in the hippocampus and the cortex the synthesis of BDNF is influenced by neuronal activity either positively (glutamate transmitter system) or negatively (GABA transmitter system).
Description: A polyclonal antibody for BDNF from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the N-terminal of human BDNF. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BDNF antibody is conjugated to Alkaline Phosphatase.
Description: BDNF is a member of the NGF family of neurotrophic growth factors. Like other members of this family, BDNF supports neuron proliferation and survival. BDNF can bind to a low affinity cell surface receptor called LNGFR, which also binds other neurotrophins such as NGF, NT-3 and NT-4. However, BDNF mediates its neurotrophic properties by signaling through a high affinity cell surface receptor called gp145/trkB. BDNF is expressed as the C-terminal portion of a 247 amino acid polypeptide precursor, which also contains a signal sequence of 18 amino acid residues and a propeptide of 110 amino acid residues. Recombinant Human BDNF is a 27.0 kDa homodimer of two 120 amino acid subunits linked by strong non-covalent interactions. Human and Mouse BDNF sequences are identical.
Description: BDNF is a member of the NGF family of neurotrophic growth factors. Like other members of this family, BDNF supports neuron proliferation and survival. BDNF can bind to a low affinity cell surface receptor called LNGFR, which also binds other neurotrophins such as NGF, NT-3 and NT-4. However, BDNF mediates its neurotrophic properties by signaling through a high affinity cell surface receptor called gp145/trkB. BDNF is expressed as the C-terminal portion of a 247 amino acid polypeptide precursor, which also contains a signal sequence of 18 amino acid residues and a propeptide of 110 amino acid residues. Recombinant Human BDNF is a 27.0 kDa homodimer of two 120 amino acid subunits linked by strong non-covalent interactions. Human and Mouse BDNF sequences are identical.
Description: BDNF is a member of the NGF family of neurotrophic growth factors. Like other members of this family, BDNF supports neuron proliferation and survival. BDNF can bind to a low affinity cell surface receptor called LNGFR, which also binds other neurotrophins such as NGF, NT-3 and NT-4. However, BDNF mediates its neurotrophic properties by signaling through a high affinity cell surface receptor called gp145/trkB. BDNF is expressed as the C-terminal portion of a 247 amino acid polypeptide precursor, which also contains a signal sequence of 18 amino acid residue and a propeptide of 110 amino acid residues. Recombinant human BDNF is a 27.0 kDa homodimer of two 120 amino acid subunits linked by strong non-covalent interactions. Human and Mouse BDNF sequences are identical.
Downregulation of prolonged noncoding RNA SNHG6 rescued propofol-induced cytotoxicity in human induced pluripotent stem cell-derived cardiomyocytes
Background: Propofol (PPF) overdose is a unusual nevertheless lethal scenario, which can lead to excessive cardiac failure. On this analysis, we established an in vitro PPF-induced cardiac cytotoxicity model, and study the purposeful perform of prolonged non-coding RNA (lncRNA) small nucleolar RNA host gene 6 (SNHG6).
Methods: Human induced pluripotent stem cell-derived cardiomyocytes (HiPSC-CMs) had been uncovered to PPF in vitro. PPF-induced cytotoxic outcomes had been measured. PPF-induced SNHG6 expression change in HiPSC-CMs had been monitored by qRT-PCR. SNHG6 was downregulated in HiPSC-CMs to have a look at its perform in PPF-induced cardiac cytotoxicity.
The expression of competing endogenous RNA (ceRNA) candidate of SNHG6, human microRNA-186-5p (hsa-miR-186-5p) was moreover investigated in PPF-exposed HiPSC-CMs. Capabilities of hsa-miR-186-5p had been extra investigated in PPF-exposed and SNHG6-downregulated HiPSC-CMs.
Outcomes: PPF induced vital cytotoxicity, along with SNHG6 upregulation in HiPSC-CMs. SNHG6 downregulation had rescuing outcomes on PPF-induced cardiac cytotoxicity. Twin-luciferase train assay confirmed that hsa-miR-186-5p was the ceRNA candidate of SNHG6. QRT-PCR confirmed hsa-miR-186-5p expression was reversely correlated with SNHG6 in PPF-exposed HiPSC-CMs. Suppressing hsa-miR-186-5p lowered the rescuing outcomes of SNHG6-downregulation on PPF-induced cardiac cytotoxicity.
Conclusions: SNHG6/hsa-miR-186-5p can modulate PPF-induced cardiac cytotoxicity in HiPSC-CMs, and thus is also a future drug objective to forestall PPF infusion syndrome.
Spherical RNA GLIS2 promotes colorectal most cancers cell motility by activation of the NF-κB pathway
Spherical RNAs (circRNAs) are a newly discovered type of natural molecule that belongs to the noncoding RNA family. Plentiful proof has confirmed that circRNAs are involved throughout the growth of various cancers. Nonetheless, the precise options of circRNAs in colorectal most cancers (CRC) keep elusive. On this analysis, we investigated the differentially expressed circRNAs in three pairs of most cancers tissue and adjoining common tissue of CRC.
We revealed that circGLIS2 expression was larger in CRC tissue and cell traces. Purchase-and-loss carry out assays confirmed that circGLIS2 was involved throughout the regulation of cell migration. Moreover, overexpressing circGLIS2 in CRC cells activated the NF-κB pathway and induced pro-inflammatory chemokine manufacturing, which evoked tumor-associated irritation by recruiting leukocytes. In flip, when probably the most cancers cells had been uncovered to the supernatant of circGLIS2 overexpressed most cancers cells, they’d been endowed with the pliability of migration and chemokines manufacturing.
Furthermore, the rescue assay confirmed that circGLIS2 activated NF-κB signaling and promoted cell migration by sponging miR-671. Basic, our analysis reveals that circGLIS2, performing as a potential oncogene, maintains the irregular activation state of the NF-κB signaling pathway by the miR-671 sponge mechanism in CRC cells. This analysis provides a scientific basis for specializing in circGLIS2 in colorectal most cancers interventions.
The RNA binding protein FMR1 controls selective exosomal miRNA cargo loading all through irritation
Cells reply to inflammatory sickness states by releasing exosomes containing extraordinarily explicit protein and RNA cargos, nevertheless how irritation alters cargo specificity and secretion of exosomes is unknown. We current that can improve in exosome secretion induced by each viral an an infection or LPS/ATP publicity consequence from inflammasome activation and subsequent caspase-1-dependent cleavage of the trafficking adaptor protein RILP.
This cleaved kind of RILP promotes the movement of multivesicular our our bodies in direction of the cell periphery and induces selective exosomal miRNA cargo loading. We have got acknowledged a regular transient sequence motif present in miRNAs that are selectively loaded into exosomes after RILP cleavage.
This motif binds the RNA binding protein FMR1 and directs miRNA loading into exosomes by interaction with components of the ESCRT (endosomal sorting superior required for transport) pathway. These outcomes level out that inflammasome-mediated RILP cleavage, and sequence-specific interactions between miRNAs and FMR1, play an enormous perform in exosome cargo loading and enhanced secretion all through cellular inflammatory responses.
Description: KLK15 Human Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 249 amino acids (17-256a.a.) and having a molecular mass of 27.4kDa (Molecular size on SDS-PAGE will appear at approximately 28-40kDa).;KLK15 is expressed with a 6 amino acids His tag at C-Terminus and purified by proprietary chromatographic techniques.
Human Kallikrein-15 (KLK15) AssayLite™ Antibody (RPE Conjugate)
Description: The human tissue kallikrein (KLK) gene family contains 15 members that play important roles in cancer. Notably, kallikrein-1, also known as tissue kallikrein, cleaves kininogen to release the vasoactive kinin peptide, bradykinin or lysyl-bradykinin. Kallikrein-3, called prostate specific antigen (PSA), is an established tumor marker that aids in the diagnosis, staging, and follow up of prostate cancer. Kallikrein-4 is specifically expressed in the prostate and over-expressed in prostate cancer. Kallikrein-5 is widely expressed but found at high levels in skin, breast, brain and testis; over-expression is an indicator of poor prognosis in ovarian cancer. Kallikrein-8 is expressed in the brain and is a novel marker of ovarian and cervical cancer.
Description: The human tissue kallikrein (KLK) gene family contains 15 members that play important roles in cancer. Notably, kallikrein-1, also known as tissue kallikrein, cleaves kininogen to release the vasoactive kinin peptide, bradykinin or lysyl-bradykinin. Kallikrein-3, called prostate specific antigen (PSA), is an established tumor marker that aids in the diagnosis, staging, and follow up of prostate cancer. Kallikrein-4 is specifically expressed in the prostate and over-expressed in prostate cancer. Kallikrein-5 is widely expressed but found at high levels in skin, breast, brain and testis; over-expression is an indicator of poor prognosis in ovarian cancer. Kallikrein-8 is expressed in the brain and is a novel marker of ovarian and cervical cancer.
Description: The human tissue kallikrein (KLK) gene family contains 15 members that play important roles in cancer. Notably, kallikrein-1, also known as tissue kallikrein, cleaves kininogen to release the vasoactive kinin peptide, bradykinin or lysyl-bradykinin. Kallikrein-3, called prostate specific antigen (PSA), is an established tumor marker that aids in the diagnosis, staging, and follow up of prostate cancer. Kallikrein-4 is specifically expressed in the prostate and over-expressed in prostate cancer. Kallikrein-5 is widely expressed but found at high levels in skin, breast, brain and testis; over-expression is an indicator of poor prognosis in ovarian cancer. Kallikrein-8 is expressed in the brain and is a novel marker of ovarian and cervical cancer.
Description: The human tissue kallikrein (KLK) gene family contains 15 members that play important roles in cancer. Notably, kallikrein-1, also known as tissue kallikrein, cleaves kininogen to release the vasoactive kinin peptide, bradykinin or lysyl-bradykinin. Kallikrein-3, called prostate specific antigen (PSA), is an established tumor marker that aids in the diagnosis, staging, and follow up of prostate cancer. Kallikrein-4 is specifically expressed in the prostate and over-expressed in prostate cancer. Kallikrein-5 is widely expressed but found at high levels in skin, breast, brain and testis; over-expression is an indicator of poor prognosis in ovarian cancer. Kallikrein-8 is expressed in the brain and is a novel marker of ovarian and cervical cancer.
Description: The human tissue kallikrein (KLK) gene family contains 15 members that play important roles in cancer. Notably, kallikrein-1, also known as tissue kallikrein, cleaves kininogen to release the vasoactive kinin peptide, bradykinin or lysyl-bradykinin. Kallikrein-3, called prostate specific antigen (PSA), is an established tumor marker that aids in the diagnosis, staging, and follow up of prostate cancer. Kallikrein-4 is specifically expressed in the prostate and over-expressed in prostate cancer. Kallikrein-5 is widely expressed but found at high levels in skin, breast, brain and testis; over-expression is an indicator of poor prognosis in ovarian cancer. Kallikrein-8 is expressed in the brain and is a novel marker of ovarian and cervical cancer.
Description: The human tissue kallikrein (KLK) gene family contains 15 members that play important roles in cancer. Notably, kallikrein-1, also known as tissue kallikrein, cleaves kininogen to release the vasoactive kinin peptide, bradykinin or lysyl-bradykinin. Kallikrein-3, called prostate specific antigen (PSA), is an established tumor marker that aids in the diagnosis, staging, and follow up of prostate cancer. Kallikrein-4 is specifically expressed in the prostate and over-expressed in prostate cancer. Kallikrein-5 is widely expressed but found at high levels in skin, breast, brain and testis; over-expression is an indicator of poor prognosis in ovarian cancer. Kallikrein-8 is expressed in the brain and is a novel marker of ovarian and cervical cancer.
